Patent application number | Description | Published |
20110088578 | Compressible roll top of former for multiribbon transport - A folder superstructure includes a former, a first top of former roll located upstream of the former and having a compressible outer layer and a second top of former roll forming a nip with the first top of former roll. A method for operating a printing press is also provided. | 04-21-2011 |
20120145018 | CLOSED LOOP COLOR CONTROL OF SELECTED REGIONS USING SOLID COLOR REGIONS WITHIN IMAGES - A color control system for use in a printing press is provided. The system includes a controller for reviewing digital data for a print job and identifying solid color regions of the print job that are greater than a predetermined size, a user interface allowing an operator to select solid color regions identified by the controller, a sensor for measuring a characteristic of the selected solid color regions of the print job on a printed substrate, the controller determining measured values of the characteristic for each of the selected solid color regions, and at least one inking unit for supplying ink in a plurality of ink zones to a plate cylinder, the controller varying the ink supplied to ink zones including the solid color regions as function of a difference between the measured value of the characteristic of each selected solid color region and a predetermined target value of the characteristic. A method for controlling printing of a printing press is also provided. | 06-14-2012 |
20130291745 | METHOD AND SYSTEM FOR INSTANTANEOUSLY DETERMINING PRINTING FLUID VOLUME CONSUMED IN A PRINTING PRESS - A method for calculating an instantaneous total volume of printing fluid used in a printing press is provided. The method includes inputting parameters of a printing fluid dispenser into a controller, calculating an instantaneous total volume of printing fluid consumed by the printing fluid dispenser using the controller and displaying the calculated instantaneous total volume of printing fluid on a human machine interface. A printing press is also provided. | 11-07-2013 |
20140158005 | FORCED ENERGY CURED INK DELIVERY IN A PRINTING UNIT - An ink delivery system includes a closed or closable ink container holding an ink supply. The ink container ink has an inlet and outlet. The inlet and outlet are arranged in the ink container to hold pressurized air when the ink container is closed and partially filled with ink. An air delivery system supplies pressurized air to the ink container via the inlet. A pump is connected to the outlet of the ink container, the pump receiving ink from the ink container; and an ink fountain receives ink from the pump. Preferably, the ink is ultraviolet or electron beam ink. | 06-12-2014 |
20150090136 | CLOSED LOOP INK THICKNESS CONTROL SYSTEM WITH REDUCED SUBSTRATE WASTE IN A PRINTING PRESS - A method is provided of charging an inker in a lithographic printing press. The method comprises placing all of the printing units of the printing press in an off impression position, with a continuous substrate passing through the printing units, each printing unit including a blanket cylinder; and in one or more printing units of the plurality of printing units, moving the takeaway roller into contact with the blanket cylinder of the printing unit. Thereafter, the method includes driving the ink train, plate cylinder, blanket cylinder and the take away roller at a first surface speed, whereby the ink from the ink train transmitted to the plate cylinder from the ink train, from the plate cylinder to the blanket cylinder, and from the blanket cylinder to the take away roller; and during said driving step, keeping the continuous substrate stationary or moving the continuous substrate at a second surface speed less than 50% of the first surface speed. Also provided is a closed loop control system for controlling the ink film thickness applied to a printed substrate in a lithographic printing press. | 04-02-2015 |
20150090137 | INDEPENDENT INKER CONTROL AND METHOD - A method of inking a substrate in a printing press is provided. The printing press includes a plurality of printing units, each printing unit includes a blanket cylinder, a plate cylinder and an inker. The method includes the steps of running the plate cylinder, blanket cylinder and inker at a press speed, driving the inker independently, printing on a substrate with a desired ink film thickness at the press speed and stopping the press for a press stop event. Stopping the press further includes stopping the inker at a maximum stop rate, stopping the plate cylinder and blanket cylinder at a normal stop rate and moving the plate cylinder and blanket cylinder into an off impression position. The method further includes ramping the plate cylinder and blanket cylinder up to a desired press speed, ramping the inker up to press independently so as to match the speed of plate cylinder, returning the plate cylinder and blanket cylinder to an on impression position and printing on the substrate with the desired ink film thickness at the desired press speed. | 04-02-2015 |
Patent application number | Description | Published |
20110015178 | Amido-Thiophene Compounds and Their Use - The present invention pertains generally to the field of therapeutic compounds. More specifically the present invention pertains to certain amido-thiophene compounds that, inter alia, inhibit 11β-hydroxysteroid dehydrogenase type 1 (11β-HSD1). The present invention also pertains to pharmaceutical compositions comprising such compounds, and the use of such compounds and compositions, both in vitro and in vivo, to inhibit 11β-hydroxysteroid dehydrogenase type 1; to treat disorders that are ameliorated by the inhibition of 11β-hydroxysteroid dehydrogenase type 1; to treat the metabolic syndrome, which includes disorders such as type 2 diabetes and obesity, and associated disorders including insulin resistance, hypertension, lipid disorders and cardiovascular disorders such as ischaemic (coronary) heart disease; to treat CNS disorders such as mild cognitive impairment and early dementia, including Alzheimer's disease; etc. | 01-20-2011 |
20120095046 | Amido-Isothiazole Compounds and Their Use as Inhibitors of 11Beta-HSD1 for the Treatment of Metabolic Syndrome and Related Disorders - The present invention pertains generally to the field of therapeutic compounds. More specifically the present invention pertains to certain amido-isothiazole compounds that, inter alia, inhibit 11β-hydroxysteroid dehydrogenase type 1 (11β-HSD1). The present invention also pertains to pharmaceutical compositions comprising such compounds, and the use of such compounds and compositions, both in vitro and in vivo, to inhibit 11β-hydroxysteroid dehydrogenase type 1; to treat disorders that are ameliorated by the inhibition of 11β-hydroxysteroid dehydrogenase type 1; to treat the metabolic syndrome, which includes disorders such as type 2 diabetes and obesity, and associated disorders including insulin resistance, hypertension, lipid disorders and cardiovascular disorders such as ischaemic (coronary) heart disease; to treat CNS disorders such as mild cognitive impairment and early dementia, including Alzheimer's disease; etc. | 04-19-2012 |
20120172393 | (4-Phenyl-piperidin-1-yl)-[5-(1H-pyrazol-4-yl)-thiophen-3-yl]-methanone Compounds and Their Use - The present invention pertains generally to the field of therapeutic compounds. More specifically the present invention pertains to certain (4-phenyl-piperidin-1-yl)-[5-(1H-pyrazol-4-yl)-thiophen-3-yl]-methanone compounds that, inter alia, inhibit 11β-hydroxysteroid dehydrogenase type 1 (11β-HSD1). The present invention also pertains to pharmaceutical compositions comprising such compounds, and the use of such compounds and compositions, both in vitro and in vivo, to inhibit 11β-hydroxysteroid dehydrogenase type 1; to treat disorders that are ameliorated by the inhibition of 11β-hydroxysteroid dehydrogenase type 1; to treat the metabolic syndrome, which includes disorders such as type 2 diabetes and obesity, and associated disorders including insulin resistance, hypertension, lipid disorders and cardiovascular disorders such as ischaemic (coronary) heart disease; to treat CNS disorders such as mild cognitive impairment and early dementia, including Alzheimer's disease; etc. | 07-05-2012 |
20130012545 | Amido-Thiophene Compounds and Their Use - The present invention pertains generally to the field of therapeutic compounds. More specifically the present invention pertains to certain amido-thiophene compounds that, inter alia, inhibit 11β-hydroxysteroid dehydrogenase type 1 (11β-HSD1). The present invention also pertains to pharmaceutical compositions comprising such compounds, and the use of such compounds and compositions, both in vitro and in vivo, to inhibit 11β-hydroxysteroid dehydrogenase type 1; to treat disorders that are ameliorated by the inhibition of 11β-hydroxysteroid dehydrogenase type 1; to treat the metabolic syndrome, which includes disorders such as type 2 diabetes and obesity, and associated disorders including insulin resistance, hypertension, lipid disorders and cardiovascular disorders such as ischaemic (coronary) heart disease; to treat CNS disorders such as mild cognitive impairment and early dementia, including Alzheimer's disease; etc. | 01-10-2013 |
20130123268 | 3,3-DISUBSTITUTED-(8-AZA-BICYCLO[3.2.1]OCT-8-YL)-[5-(1H-PYRAZOL-4-YL)-THIO- PHEN-3-YL]-METHANONES AS INHIBITORS OF 11 (BETA)-HSD1 - The present invention pertains generally to the field of therapeutic compounds. More specifically the present invention pertains to certain 3,3-disubstituted-(8-aza-bicyclo[3.2.1]oct-8-yl)-[5-(1H-pyrazol-4-yl)-thiophen-3-yl]-methanone, 3,3-disubstituted-(6-aza-bicyclo[3.1.1]hept-6-yl)-[5-(1H-pyrazol-4-yl)-thiophen-3-yl]-methanone, and 4,4-disubstituted piperidin-1-yl)-[5-(1H-pyrazol-4-yl)-thiophen-3-yl]-methanone compounds of the following formula that, inter alia, inhibit 11β-hydroxysteroid dehydrogenase type 1 (11β-HSD1). The present invention also pertains to pharmaceutical compositions comprising such compounds, and the use of such compounds and compositions, both in vitro and in vivo, to inhibit 11β-hydroxysteroid dehydrogenase type 1; to treat disorders that are ameliorated by the inhibition of 11β-hydroxysteroid dehydrogenase type 1; to treat the metabolic syndrome, which includes disorders such as type 2 diabetes and obesity, and associated disorders including insulin resistance, hypertension, lipid disorders and cardiovascular disorders such as ischaemic (coronary) heart disease; to treat CNS disorders such as mild cognitive impairment and early dementia, including Alzheimer's disease; etc. | 05-16-2013 |